Logo

SRPT

Sarepta Therapeutics, Inc.

SRPT

Sarepta Therapeutics, Inc. • NASDAQ
$21.32 ▲ 1.79% (+0.38)
Market Cap $2.09 B
52w High $138.81
52w Low $10.42
Dividend Yield 0%
P/E -7.54
Volume 1.62M
Outstanding Shares 97.98M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $399.356M ▼ $299.239M ▼ $-179.947M ▼ -45.059% ▼ $-1.795 ▼ $-181.828M ▼
Q2-2025 $611.091M ▼ $342.956M ▼ $196.892M ▲ 32.22% ▲ $2.01 ▲ $169.706M ▲
Q1-2025 $744.856M ▲ $907.678M ▲ $-447.508M ▼ -60.08% ▼ $-4.6 ▼ $-369.037M ▼
Q4-2024 $658.412M ▲ $364.427M ▲ $159.049M ▲ 24.156% ▲ $1.65 ▲ $186.673M ▲
Q3-2024 $467.172M $353.285M $33.611M 7.195% $0.35 $48.73M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $850.993M ▲ $3.493B ▼ $2.173B ▼ $1.32B ▼
Q2-2025 $800.139M ▲ $3.68B ▲ $2.322B ▼ $1.357B ▲
Q1-2025 $522.762M ▼ $3.465B ▼ $2.323B ▼ $1.143B ▼
Q4-2024 $1.355B ▲ $3.963B ▲ $2.435B ▲ $1.528B ▲
Q3-2024 $1.198B $3.6B $2.379B $1.221B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-179.947M ▼ $0 ▼ $0 ▼ $0 ▲ $102.479M ▼ $0 ▼
Q2-2025 $196.892M ▲ $261.337M ▲ $32.211M ▲ $-23.817M ▼ $269.731M ▲ $231.779M ▲
Q1-2025 $-447.508M ▼ $-583.437M ▼ $-291.177M ▼ $12.471M ▼ $-862.143M ▼ $-629.326M ▼
Q4-2024 $159.049M ▲ $92.046M ▲ $764.118M ▲ $48.991M ▲ $905.155M ▲ $53.964M ▲
Q3-2024 $33.611M $-70.699M $-128.825M $13.757M $-185.767M $-107.962M

Five-Year Company Overview

Income Statement

Income Statement Sarepta has shifted from years of sizable losses to posting a solid profit most recently, driven by steadily growing sales of its Duchenne muscular dystrophy treatments and gene therapy. Revenue has increased meaningfully every year, and margins have improved as the company scales, suggesting better cost discipline and operating leverage. That said, profitability is still relatively new and likely sensitive to R&D intensity, pricing pressure, and any setbacks with its key products or label expansions.

Balance Sheet

Balance Sheet The balance sheet looks stronger than a few years ago. Total assets have grown, shareholder equity has rebuilt, and cash has bounced back after dipping, although it’s still below prior peak levels. Debt remains significant but not extreme relative to the asset base, and the improving equity position reduces balance sheet strain. The overall picture is of a company that has moved from a more fragile state toward a sturdier financial footing, but one that still needs to manage debt and cash carefully given the volatility of biotech cash flows.

Cash Flow

Cash Flow Despite showing an accounting profit, Sarepta is still consuming cash from its operations, though the cash burn has been shrinking over time. Free cash flow remains negative, reflecting high R&D spending and ongoing investment in manufacturing and commercialization. Capital spending is modest but rising, which fits with a company building out its platform and infrastructure. The key watchpoint is whether growing product revenue can soon consistently cover operating and investment needs, reducing reliance on the balance sheet or external funding.

Competitive Edge

Competitive Edge Sarepta holds a leading position in treatments for Duchenne muscular dystrophy, with multiple approved exon-skipping drugs and the first gene therapy for the disease. This brings strong brand recognition, deep ties with patient communities, and a meaningful installed commercial footprint. Robust intellectual property and the complexity of genetic medicines create real barriers for new entrants. However, its focus on rare diseases also means dependence on a few key products, exposure to regulatory scrutiny and safety issues, and the risk that competing genetic or gene-editing therapies could challenge its leadership over time.

Innovation and R&D

Innovation and R&D The company is heavily research-driven, with a broad toolkit that spans RNA-targeted drugs, gene therapy, and early work in gene editing and RNA interference. Its next-generation PPMO platform aims to deliver more potent and convenient DMD treatments, while gene therapy programs target both DMD and limb-girdle muscular dystrophies. New partnerships expand its reach into additional rare and serious diseases, diversifying the pipeline beyond its historical core. This innovation engine offers substantial long-term opportunity but also brings high scientific, regulatory, and execution risk, as seen in recent safety concerns and trial holds.

Summary

Sarepta has evolved from a cash-burning, loss-making biotech into a more mature genetic-medicine company with growing sales, newfound profitability, and a stronger balance sheet. Its leadership in Duchenne muscular dystrophy, first-mover status in gene therapy for the disease, and deep relationships with the rare disease community underpin a solid competitive position. At the same time, the business remains complex and risky: cash flows are not yet consistently self-funding, the company relies on a concentrated product set, and its ambitious R&D portfolio faces the usual clinical and regulatory uncertainties of cutting-edge biotech. Overall, Sarepta combines meaningful commercial traction with a high-risk, high-innovation pipeline that could significantly reshape its financial profile—positively or negatively—over the coming years.

NEWS

November 25, 2025 · 8:57 AM UTC

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Read more

November 24, 2025 · 7:30 AM UTC

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Read more

November 20, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

Read more

November 14, 2025 · 2:54 PM UTC

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Read more

November 3, 2025 · 4:05 PM UTC

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Read more